# A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct07376382/  
OnCo record `nct07376382` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SYS6010 and osimertinib in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.

## Summary

A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC is a phase 3, randomised interventional study registered as NCT07376382 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 680 participants, started 2026-06-01 and due to reach its primary completion in 2026-12-12. Interventions recorded: SYS6010; Osimertinib; platinum-pemetrexed. Conditions listed: NSCLC. Primary outcome: Progression Free Survival(PFS) evaluated by IRC. Lung eligibility wording from the registry: "Patients with pathologically confirmed locally advanced or metastatic NSCLC, including: patients with stage IIIB or IIIC based on AJCC staging version 8 who are not suitable for surgical resection or radical chemoradiotherapy, or patients with stage IV NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: SYNSTAR-02
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07376382
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase III Clinical Trial to Evaluate the Safety and Efficacy of SYS6010 in Combination With Osimertinib in Patients With EGFR-mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 680

## Sources

- ClinicalTrials.gov NCT07376382: https://clinicaltrials.gov/study/NCT07376382

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [SYS6010](https://onco.cc/drugs/sys6010/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07376382.json